Malignant Peritoneal Mesothelioma With EWSR1-ATF1 Fusion: A Case Report

Malignant Peritoneal Mesothelioma With EWSR1-ATF1 Fusion: A Case Report

Malignant mesothelioma with EWSR1-ATF1 fusion is a rare malignancy described in young adults without asbestos exposure. To the best of our knowledge, outcomes to local and systemic therapies for this subtype of malignant mesothelioma have not been described. This case report describes the clinical c...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Helen Ke, MBBS (Hons), Anthony J. Gill, AM, MBBS, FRCPA, Catriona McKenzie, MBBS (Hons1), FRCPA, James G. Kench, MBBS, Bsc(Med), FRCPA, Renee C.F. Chan, MBBS(Hons1), FRCPA, Nick Pavlakis, BSc, MBBS, MMed(Clin. Epi), PhD, FRACP, Michael Fulham, MBBS(Hons), FRACP, Cherry Koh, MBBS (Hons), MS, FRACS, Steven Kao, BHB, MBChB, PhD, FRACP
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
Case report
Peritoneal mesothelioma
EWSR1
ATF1
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/4276d0c706c24f83ba19a45b265d9305
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Malignant mesothelioma with EWSR1-ATF1 fusion is a rare malignancy described in young adults without asbestos exposure. To the best of our knowledge, outcomes to local and systemic therapies for this subtype of malignant mesothelioma have not been described. This case report describes the clinical course of a 19-year-old man diagnosed with malignant peritoneal mesothelioma with EWSR1-ATF1 fusion localized to the abdomen. His disease followed an aggressive course and resulted in limited survival (18 mo). There was treatment resistance to several lines of conventional local and systemic treatments for peritoneal mesothelioma and biologically targeted MET inhibition with crizotinib. More research is required in this rare subtype of peritoneal mesothelioma.

Ejemplares similares